WORCESTER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX News
Network) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the
leader in drug delivery for metabolic diseases through the inner
lining of the mouth, announced today that it will be making three
poster presentations at the 46th Annual Meeting of the European
Society of Pediatric Endocrinology in Helsinki, Finland June 27 --
30, 2007 (www.espe2007.org).
The three abstracts feature Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, including a study in juveniles. The Company previously announced that it is preparing for a Phase 3 clinical trial of Generex Oral-lyn in centres in the United States, Europe, and Canada. The abstracts are:
6-Month Study on the Safety and Efficacy of Oral Insulin (Generex Oral-lyn(tm)) Administered at Lunchtime in Juvenile Type-1 DM Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs;
Comparison Of Metabolic Control Of Pre-Prandial S.C. Regular Insulin Versus Prandia Oral Insulin (Generex Oral-lyn(tm)) In Adult Type-1 DM Subjects Maintained on Basal S.C. BID Isophane Insulin (NPH), by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador; and
Near Normalization of Metabolic Control in Type-1 DM Using Conventional Insulin Therapy and a 13-Point Method Designed to Enhance Compliance, by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, together with Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs.
The European Society for Paediatric Endocrinology (ESPE) is an international organization with several hundred members from over 45 countries whose aim is to promote the highest levels of knowledge, research, education, and clinical practice of paediatric endocrinology and metabolism throughout the world. Founded in 1962, ESPE has increased in both size and scope, becoming one of the largest and most leading international scientific communities of paediatric endocrinologists.
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at http://www.generex.com. Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications , potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Generex Biotechnology Corp.